FindTrial
Sign In

PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

Comparative Clinical and Biochemical Study Evaluating the Effect of Proton Pump I Nhibitors Versus Histamine 2 Receptor Antagonists as an Adjuvant With Chemotherapy in Patients With Non-hodgkin Lymphoma.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03647072
Enrollment
60
Registered
2018-08-27
Start date
2018-08-01
Completion date
2027-12-31
Last updated
2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Brief summary

The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.

Detailed description

The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump Inhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma to compare the difference in efficacy.

Interventions

DRUGCHOP

CHOP only

DRUGCHOP Plus Lanzoprazole

CHOP plus Lanzoprazole 60 mg

DRUGCHOP Plus Famotidine

CHOP Plus Famotidine 40 mg

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* DLBCL Lymphoma subtype --No comorbid disease

Exclusion criteria

* Pregnancy * Peptic ulcer * Severe cardiac disease * Osteoporosis

Design outcomes

Primary

MeasureTime frameDescription
Number of patients eith radiological and clinical improvement6 monthsNumber of patients eith radiological and clinical improvement after cycles of chemotherapy

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, MD
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026